Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

• Status: Withdrawn
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Anidulafungin; Echinocandins; Voriconazole

Criteria

Inclusion Criteria:

• Diagnosis of proven, probable, or possible invasive aspergillosis.

• Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion Criteria:

• Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.

• Chronic invasive aspergillosis.

• Receipt of antifungal treatment for more than 96 hours.

• Severe liver dysfunction.